KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Q3 2025 value amounting to $45.9 million.

  • Rigel Pharmaceuticals' Receivables - Net rose 5020.44% to $45.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year increase of 5020.44%. This contributed to the annual value of $41.6 million for FY2024, which is 3621.93% up from last year.
  • Rigel Pharmaceuticals' Receivables - Net amounted to $45.9 million in Q3 2025, which was up 5020.44% from $39.9 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Receivables - Net high stood at $142.2 million for Q1 2021, and its period low was $3.0 million during Q1 2025.
  • Moreover, its 5-year median value for Receivables - Net was $23.5 million (2023), whereas its average is $30.5 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Receivables - Net skyrocketed by 137199.79% in 2021, and later tumbled by 8928.23% in 2022.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Receivables - Net stood at $15.5 million in 2021, then increased by 29.27% to $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then rose by 10.36% to $45.9 million in 2025.
  • Its last three reported values are $45.9 million in Q3 2025, $39.9 million for Q2 2025, and $3.0 million during Q1 2025.